Company Profile
Moleculin Biotech, Inc. Stock Price, News & Catalysts
- Ticker:
- MBRX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
0.61 USD (-0.85%)
Close
Last updated: August 17, 2026
13.1M USD
Market cap
Why the stock is moving
Following the latest company update, āMoleculin Biotech Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of Pivotal MIRACLE Trialā, MBRX closed up 7.16% at $0.6122 on Aug 14, 2026. The move occurred in the trading session associated with this clinical readout update.
Company overview
Late-Stage Oncology Pipeline
Moleculin Biotech is a clinical-stage company developing treatments for difficult-to-treat cancers and viral diseases. Its portfolio centers on Annamycin in acute myeloid leukemia, supported by earlier-stage programs targeting oncogenic transcription and tumor metabolism.
Annamycin
Annamycin is a next-generation anthracycline designed to avoid multidrug-resistance mechanisms and reduce the cardiotoxicity associated with conventional anthracyclines. The candidate is being developed in relapsed or refractory AML and has also been studied in soft-tissue sarcoma metastatic to the lungs.
MIRACLE Program
MIRACLE is an adaptive pivotal Phase 2/3 study evaluating Annamycin with cytarabine, a regimen referred to as AnnAraC, in second-line relapsed or refractory AML. Part A is designed to enroll approximately 90 patients and identify the dose and regimen to carry into the confirmatory portion of the study.
Additional Development Programs
The pipeline also includes WP1066, a modulator of p-STAT3 and other oncogenic transcription factors under evaluation in brain and pancreatic cancers, and WP1122, a metabolic antitumor and antiviral platform. These programs provide development opportunities beyond Annamycin and hematologic malignancies.
Future catalysts
- Completion of enrollment in Part A of the MIRACLE trial in September 2026.
- Initiation of an Atlantic Health investigator-sponsored Annamycin study in pancreatic cancer in the second half of 2026.
- Unblinding and efficacy readout from MIRACLE Part A between December 2026 and February 2027.
- Initiation of MIRACLE Part B in the first half of 2027.
- Planned start of a rolling NDA submission for Annamycin under an accelerated-approval pathway in 2028.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Moleculin Biotech, Inc. (MBRX)?
Moleculin Biotech, Inc. (MBRX) most recently closed at 0.61 USD, a -0.85% move versus the previous session.
What is the market cap of Moleculin Biotech, Inc. (MBRX)?
Moleculin Biotech, Inc. currently has a market capitalization of 13.1M USD on BioPharmSignal.
What does Moleculin Biotech, Inc. do?
Late-Stage Oncology Pipeline Moleculin Biotech is a clinical-stage company developing treatments for difficult-to-treat cancers and viral diseases. Its portfolio centers on Annamycin in acute myeloid leukemia, supported by earlier-stage programs targeting oncogenic transcription and tumor metabolism. Annamycin Annamycin is a next-generation anthracycline...
On which exchange is MBRX stock listed?
Moleculin Biotech, Inc. (MBRX) is associated with NASDAQ, United States, Biopharma.
What is Late-Stage?
Late-Stage Oncology Pipeline Moleculin Biotech is a clinical-stage company developing treatments for difficult-to-treat cancers and viral diseases.
Which conditions is Moleculin Biotech, Inc. targeting with Late-Stage?
Moleculin Biotech, Inc. is associated with oncology, cancer therapeutics, metabolic disease based on its company overview and current catalyst commentary.
How does Moleculin Biotech, Inc. describe recent progress with Late-Stage?
Completion of enrollment in Part A of the MIRACLE trial in September 2026. Initiation of an Atlantic Health investigator-sponsored Annamycin study in pancreatic cancer in the second half of 2026. Unblinding and efficacy readout from MIRACLE Part A between December 2026 and February 2027. Initiation of MIRACLE Part B in the first half of 2027. Planned start...
What is Oncology?
Late-Stage Oncology Pipeline Moleculin Biotech is a clinical-stage company developing treatments for difficult-to-treat cancers and viral diseases.